Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jerel A. Banks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
- Beta
- 0.27
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 48.63
Financials
Revenue
$0.00-100.0%Net Income
$-12.81M-2363.4%EBITDA
$-14.31M-2441.6%Free Cash Flow
$-5.02MEPS (diluted)
$-0.27-101.3%Shares Outstanding (diluted)
46.56M+31901.4%Operating Expenses
$16.16MCash & Debt
$179.97MRevenue by Segment (annual)
$75.0KDividend per Share
$0.77Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-45.55M | $-0.98 |
| 2025 | $0.00 | $-37.92M | $-1.05 |
| 2024 | $0.00 | $-21.75M | $-2.68 |
| 2023 | $75.0K | $-19.56M | $-14.12 |
| 2022 | $73.0K | $-18.21M | $-19.31 |
| 2021 | $59.0K | $-13.88M | $-27.27 |
| 2020 | $97.0K | $-8.27M | $-69.09 |
| 2019 | $17.45M | $3.73M | $28.45 |
| 2018 | $4.40M | $-12.33M | $-103.60 |
| 2017 | $195.9K | $-5.60M | $-63.55 |
| 2016 | $258.5K | $-13.81M | $-331.56 |
| 2015 | $630.5K | $-6.71M | $-194.88 |
| 2014 | $956.2K | $-6.87M | $-76.26 |
| 2013 | $504.4K | $-3.87M | $-83.25 |
Valuation
BNTChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
95+58.33%Social Signal Score
Mentions (2)
- Newszacks.com·5h ago·Neutral
After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC) Benitec Biopharma (BNTC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
View source ↗ - Newsglobenewswire.com·11d ago·Negative
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treated A Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in October Additional interim clinical
View source ↗
Earnings
Fri, Nov 13(in 7 weeks)
Consensus estimate $-0.27 per share
Typical surprise +11.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Sep 14$-0.26 vs $-0.26beat
- Thu, May 14$-0.24 vs $-0.27beat
- Thu, Feb 12$-0.26 vs $-0.23miss
- Fri, Nov 14$-0.22 vs $-0.35beat
- Mon, Sep 22$-0.42 vs $-0.28miss
- Wed, May 14$-0.24 vs $-0.36beat
Estimates and results for BNTC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BNTC officers and directors.
- Bought
- $37.5m
- Sold
- —
40 trades
0 trades
- Suvretta Capital Management, Llcbought
- Suvretta Capital Management, Llcbought
- Suvretta Capital Management, Llcbought
- Suvretta Capital Management, Llcbought
- Suvretta Capital Management, Llcbought
- Suvretta Capital Management, Llcbought
- Suvretta Capital Management, Llcbought
- Suvretta Capital Management, Llcbought
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BNTC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.